1.Naylor, AR, Hayes, PD, Darke, S. A prospective audit of complex wound and graft infection in Great Britain and Ireland: the emergence of MRSA. Eur J Vase Endovasc Surg 2001;21:289–294.
2.Nasim, A, Thompson, MM, Naylor, AR, Bell, PR, London, NJ. The impact of MRSA on vascular surgery. Eur J Vase Endovasc Surg 2001;22:211–214.
3.Chalmers, RT, Wolfe, JH, Cheshire, NJ, et al.Improved management of infrainguinal bypass graft infection with methicillin-resistant Staphylococcus aureus. Br J Surg 1999;86:1433–1436.
4.Grimble, SA, Magee, TR, Galland, RB. Methicillin-resistant Staphylococcus aureus in patients undergoing major amputation. Eur J Vase Endovasc Surg 2001;22:215–218.
5.Taylor, MD, Napolitano, LM. Methicillin-resistant Staphylococcus aureus infections in vascular surgery: increasing prevalence. Surg Infect (Larchmt) 2004;5:180–187.
6.Cowie, SE, Ma, I, Lee, SK, Smith, RM, Hsiang, YN. Nosocomial MRSA infection in vascular surgery patients: impact on patient outcome. Vase Endovascular Surg 2005;39:327–334.
7.Nather, A, Bee, CS, Huak, CY, et al.Epidemiology of diabetic foot problems and predictive factors for limb loss. J Diabetes Complications 2008;22:77–82.
8.Richards, T, Pittathankel, AA, Purseil, R, Magee, TR, Galland, RB. MRSA in lower limb amputation and the role of antibiotic prophylaxis. J Cardiovasc Surg (Torino) 2005;46:37–41.
9.Murphy, GJ, Pararajasingam, R, Nasim, A, Dennis, MJ, Sayers, RD. Methicillin-resistant Staphylococcus aureus infection in vascular surgical patients. Ann R Coll Surg Engl 2001;83:158–163.
10.Thompson, M. An audit demonstrating a reduction in MRSA infection in a specialised vascular unit resulting from a change in infection control protocol. Eur J Vase Endovasc Surg 2006;31:609–615.
11.Morange-Saussier, V, Giraudeau, B, van der Mee, N, Lermusiaux, P, Quentin, R. Nasal carriage of methicillin-resistant Staphylococcus aureus in vascular surgery. Ann Vase Surg 2006;20:767–772.
12.Bounthavong, M, Hsu, DI, Okamoto, MP. Cost-effectiveness analysis of linezolid vs vancomycin in treating methicillin-resistant Staphylococcus awreus-complicated skin and soft-tissue infections using a decision analytic model. Int J Clin Pract 2009;63:376–386.
13.Levit, K (Thomson Reuters), Stranges, E (Thomson Reuters), Ryan, K (Thomson Reuters), Elixhauser, A (AHRQ). HCUP Facts and Figures, 2006: Statistics on Hospital-Based Care in the United States. Rockville, MD: Agency for Healthcare Research and Quality; 2008. Available at: http://www.hcup-us.ahrq.gov/reports.jsp. Accessed October 6, 1984.
14.Shannon, RP, Patel, B, Cummins, D, Shannon, AH, Ganguli, G, Lu, Y. Economics of central line-associated bloodstream infections. Am J Med Qual 2006;21(Suppl 6):7S–16S.
15.Sackett, DL, Torrance, GW. The utility of different health states as perceived by the general public. J Chronic Dis 1978;31:697–704.
16.Gold, MR, Franks, P, McCoy, KI, Fryback, DG. Toward consistency in cost-utility analyses: using national measures to create condition-specific values. Med Care 1998;36:778–792.
17.Tengs, TO, Wallace, A. One thousand health-related quality-of-life estimates. Med Care 2000;38:583–637.
18.Selai, C, Rosser, R. Eliciting EuroQol descriptive data and utility scale values from inpatients: a feasibility study. Pharmacoeconomics 1995;8:147–158.
19.Reyes, J, Hidalgo, M, Diaz, L, et al.Characterization of macrolide resistance in gram-positive cocci from Colombian hospitals: a countrywide surveillance. Int J Infect Dis 2007;11:329–336.
20.Cerveira, JJ, Lai, BK, Padberg, FT Jr, Pappas, PJ, Hobson, RW 2nd. Methicillin-resistant Staphylococcus aureus infection does not adversely affect clinical outcome of lower extremity amputations. Ann Vase Surg 2003;17:80–85.
21.Zack, J. Zeroing in on zero tolerance for central line-associated bacteremia. Am J Infect Control 2008;36:S176.e1-2.
22.Bell, C, Urbach, D, Ray, J, et al.Bias in published cost effectiveness studies: systematic review. BMJ 2006;332:699–703.
23.Shiroiwa, T, Sung, YK, Fukuda, T, Lang, HC, Bae, SC, Tsutani, K. International survey on willingness-to-pay (WTP) for one additional QALY gained: what is the threshold of cost-effectiveness?Health Econ 2009 [epub ahead of print].
25.Graves, N. Economics and preventing hospital-acquired infection. Emerg Infect Dis 2004;10:561–566.
26.Graves, N, Halton, K, Lairson, D. Economics and preventing hospital-acquired infection: broadening the perspective. Infect Control Hosp Epidemiol 2007;28:178–184.
27.Braithwaite, RS, Meitzer, DO, King, JT Jr, Leslie, D, Roberts, MS. What does the value of modern medicine say about the $50,000 per quality-adjusted life-year decision rule? Med Care 2008;46:349–356.
28.Laupacis, A, Feeny, D, Detsky, AS, Tugwell, PX. How attractive does a new technology have to be to warrant adoption and utilization? tentative guidelines for using clinical and economic evaluations. CMAJ 1992;146:473–481.
29.Ammerlaan, HS, Kluytmans, JA, Wertheim, HF, Nouwen, JL, Bonten, MJ. Eradication of methicillin-resistant Staphylococcus aureus carriage: a systematic review. Clin Infect Dis 2009;48:922–930.
30.Lautenbach, E, Nachamkin, I, Hu, B, et al.Surveillance cultures for detection of methicillin-resistant Staphylococcus aureus: diagnostic yield of anatomic sites and comparison of provider- and patient-collected samples. Infect Control Hosp Epidemiol 2009;30:380–382.
31.Marshall, C, Spelman, D. Re: is throat screening necessary to detect methicillin-resistant Staphylococcus aureus colonization in patients upon admission to an intensive care unit? J Clin Microbiol 2007;45:3855.